Source:http://linkedlifedata.com/resource/pubmed/id/19945197
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2010-2-1
|
pubmed:abstractText |
The purpose of this study was to evaluate the enhancement value of chloroquine analogs when used in combination with Akt inhibitors on the MDA-MB468, MDA-MB231 and MCF7 human breast cancer cell lines. The result showed that the combination of certain chloroquine analogs and Akt inhibitors are highly effective. In particular, the chloroquine analog N'-(7-fluoro-quinolin-4-yl)-N,N-dimethyl-ethane-1,2-diamine (compound 5) was highly effective in sensitizing cancer cell killing when combined with either Akt inhibitor 8 (1-{1-[4-(7-phenyl-1H-imidazo[4,5-g]quinoxalin-6-yl)-benzyl]-piperidin-4-yl}-1,3-dihydro-benzoimidazol-2-one) or 9 ([4-(2-chloro-4a,10a-dihydro-phenoxazin-10-yl)-butyl]-diethyl-amine hydrochloride). Importantly, the enhancement of chloroquine analogs 5 on cell killing by Akt inhibitors 8 and 9 was cancer-specific. Thus, this combinational approach is highly promising in controlling tumors with a minimum side effect. Structural analysis of effective and ineffective chloroquine analogs suggests that the 4-aminoquinoline scaffold and lateral side chain of dimethylamino functionality play an important role for the enhancement of cell killing by Akt inhibitors.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
1768-3254
|
pubmed:author | |
pubmed:copyrightInfo |
Copyright 2009 Elsevier Masson SAS. All rights reserved.
|
pubmed:issnType |
Electronic
|
pubmed:volume |
45
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
705-9
|
pubmed:meshHeading |
pubmed-meshheading:19945197-Aminoquinolines,
pubmed-meshheading:19945197-Cell Death,
pubmed-meshheading:19945197-Cell Line, Tumor,
pubmed-meshheading:19945197-Cell Proliferation,
pubmed-meshheading:19945197-Dose-Response Relationship, Drug,
pubmed-meshheading:19945197-Drug Synergism,
pubmed-meshheading:19945197-Humans,
pubmed-meshheading:19945197-Protein Kinase Inhibitors,
pubmed-meshheading:19945197-Proto-Oncogene Proteins c-akt
|
pubmed:year |
2010
|
pubmed:articleTitle |
A 4-aminoquinoline derivative that markedly sensitizes tumor cell killing by Akt inhibitors with a minimum cytotoxicity to non-cancer cells.
|
pubmed:affiliation |
Tumour Biology, Northeastern Ontario Regional Cancer Program at the Sudbury Regional Hospital, 41 Ramsey Lake Road, Sudbury, Ontario P3E 5J1, Canada.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|